A new mouse model of Alport syndrome with slower disease progression may provide a better way to study the disease’s underlying mechanisms and potential therapies, a recent study suggests. The work confirmed the existence of additional genetic factors — potentially the MYO1E gene — influencing Alport’s progression,…
Read more
Chinook Therapeutics acquired the global rights for the development and commercialization of AbbVie‘s atrasentan, an investigational compound for the treatment of people with primary glomerular kidney disease, including patients with Alport syndrome. Chinook, a Canadian biotech focused on medicines for kidney diseases, expects to launch…
Tailored gene therapy repaired two mutations associated with Alport syndrome in specialized kidney cells from Alport patients, a preclinical study found. The findings point to patient-specific gene therapy as a potential effective treatment for Alport syndrome. The study, “New frontiers to cure Alport syndrome: COL4A3 and…
Alport syndrome is a genetic condition with three different variations. Learn more about the disease here.
Mutations in the COL4A5, COL4A3, and COL4A4 genes can cause this disease. Learn more about the causes here.
Symptoms include kidney disease, hearing loss, and eye abnormalities. Learn more about the symptoms here.
Get regular updates to your inbox.
